Chronic obstructive pulmonary disease with (acute) lower respiratory infection
Methodology & AI Transparency ⓘ
Chronic obstructive pulmonary disease with (acute) lower respiratory infection Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within Asthma, COPD & Respiratory Disease practice, Chronic obstructive pulmonary disease with (acute) lower respiratory infection (ICD-10 J44.0) is stratified through lung diffusion capacity in Chronic obstructive pulmonary disease with (acute) lower respiratory infection (J44.0: (DLCO)), pairing targeted symptom control with longitudinal Blood Eosinophil Count [Chronic obstructive pulmonary disease with (acute) lower respiratory infection J44.0] surveillance.
- 2 Real-world patient consensus: Mapped to Asthma, COPD & Respiratory Disease under ICD-10-CM J44.0 for Chronic obstructive pulmonary disease with (acute) lower respiratory infection clinical workups.
- 3 Typical cash cost range: Primary evaluation for Chronic obstructive pulmonary disease with (acute) lower respiratory infection incorporates lung diffusion capacity in Chronic obstructive pulmonary disease with (acute) lower respiratory infection (J44.0: (DLCO)) and symptom diary review.
- 4 Top reported side effects / signs: Objective lab/clinical target for Chronic obstructive pulmonary disease with (acute) lower respiratory infection: Resting Pulse Oximetry in Chronic obstructive pulmonary disease with (acute) lower respiratory infection (J44.0: (SpO2)) (96% – 100% (J44.0)) and Blood Eosinophil Count [Chronic obstructive pulmonary disease with (acute) lower respiratory infection J44.0].
Ask our AI Specialists anything about Chronic obstructive pulmonary disease with (acute) lower respiratory infection
What Is Chronic obstructive pulmonary disease with (acute) lower respiratory infection?
Within Asthma, COPD & Respiratory Disease practice, Chronic obstructive pulmonary disease with (acute) lower respiratory infection (ICD-10 J44.0) is stratified through lung diffusion capacity in Chronic obstructive pulmonary disease with (acute) lower respiratory infection (J44.0: (DLCO)), pairing targeted symptom control with longitudinal Blood Eosinophil Count [Chronic obstructive pulmonary disease with (acute) lower respiratory infection J44.0] surveillance.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in lungs & asthma, Chronic obstructive pulmonary disease with (acute) lower respiratory infection (J44.0) involves bronchial smooth-muscle hyperresponsiveness [Chronic obstructive pulmonary disease with (acute) lower respiratory infection J44.0]. progression correlates with shifts in Resting Pulse Oximetry in Chronic obstructive pulmonary disease with (acute) lower respiratory infection (J44.0: (SpO2)) (96% – 100% (J44.0)).
Common Symptoms & Clinical Signs
- • Presentation of Chronic obstructive pulmonary disease with (acute) lower respiratory infection (J44.0): prolonged recovery from in Chronic obstructive pulmonary disease with (acute) lower respiratory infection (J44.0: viral respiratory infections)
- • Secondary Chronic obstructive pulmonary disease with (acute) lower respiratory infection clinical sign: declining stair-climbing stamina in Chronic obstructive pulmonary disease with (acute) lower respiratory infection (J44.0: or frequent rescue)
- • Symptom flares in Chronic obstructive pulmonary disease with (acute) lower respiratory infection correlating with Resting Pulse Oximetry in Chronic obstructive pulmonary disease with (acute) lower respiratory infection (J44.0: (SpO2)) deviation outside 96% – 100% (J44.0)
- • Functional lungs & asthma impact requiring lung diffusion capacity in Chronic obstructive pulmonary disease with (acute) lower respiratory infection (J44.0: (DLCO)) evaluation (J44.0)
Chronic obstructive pulmonary disease with (acute) lower respiratory infection Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | J44.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Asthma, COPD & Respiratory Disease | NLM Clinical Tables |
| Diagnostic / Lab Marker: Resting Pulse Oximetry in Chronic obstructive pulmonary disease with (acute) lower respiratory infection (J44.0: (SpO2)) | 96% – 100% (J44.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Blood Eosinophil Count [Chronic obstructive pulmonary disease with (acute) lower respiratory infection J44.0] | < 150 cells/uL (phenotyping marker) (J44.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Spirometry FEV1 / in Chronic obstructive pulmonary disease with (acute) lower respiratory infection (J44.0: FVC Ratio) | >= 0.75 (FEV1 >= 80% predicted) (J44.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Chronic obstructive pulmonary disease with (acute) lower respiratory infection
Treatment selection for Chronic obstructive pulmonary disease with (acute) lower respiratory infection depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Chronic obstructive pulmonary disease with (acute) lower respiratory infection)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Safety and real-world benefits of Semaglutide in Patients With Chronic Kidney: What a 12,785-Participant Study Found Semaglutide demonstrates a favourable safety profile and significant cardiorenal benefits in CKD patients, with or without T2DM. Endocrinology, diabetes & metabolism • 2025-11-15 • Meta-Analysis | N = 12,785 | 99/100 | PMID 41276951 ↗ |
| New Insights on Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart: What a 3,668-Participant Study Found Compared with placebo, a mean atrasentan exposure translated in a hazard ratio of 0.76 (95% confidence interval (CI): 0.28-0.85) for kidney events and 1.13 (95% CI: 1.03-2.20) for heart failure events. Clinical pharmacology and therapeutics • 2021-06-15 • Phase III Randomized Trial | N = 3,668 | 96/100 | PMID 33338269 ↗ |
| New Insights on Reductions in acute medication use and healthcare resource utilization in: What a 1,113-Participant Study Found Treatment with galcanezumab resulted in significant reductions in headache medication overuse and migraine headache days requiring acute medication use, with notable reductions in migraine-specific HCRU. Journal of medical economics • 2022-01-15 • Phase III Randomized Trial | N = 1,113 | 96/100 | PMID 35971655 ↗ |
| New Insights on Empagliflozin Reduces Risk of Hospitalization in Patients With Chronic Kidney: What a 6,609-Participant Study Found 1995 participants (1035 placebo, 960 empagliflozin) had ≥1 ACH (1895 ACH in placebo and 1611 in the empagliflozin 10-mg groups). Clinical therapeutics • 2025-12-15 • Phase III Randomized Trial | N = 6,609 | 96/100 | PMID 41047325 ↗ |
| New Insights on Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development,: What a 5,000-Participant Study Found Benefits also include improvements in quality of life, fewer psychiatric comorbidities, and reduced healthcare resource utilization. Medicine • 2023-07-01 • Phase III Randomized Trial | N = 5,000 | 96/100 | PMID 37499085 ↗ |
Chronic obstructive pulmonary disease with (acute) lower respiratory infection Patient Community & “People Like Me” Threads
Filter Chronic obstructive pulmonary disease with (acute) lower respiratory infection community threads and patient logs by age, biological sex, dosage, and treatment duration.